Myocardial tissue characterization in Chagas’ heart disease by cardiovascular magnetic resonance by unknown
RESEARCH Open Access
Myocardial tissue characterization in
Chagas’ heart disease by cardiovascular
magnetic resonance
Jorge A. Torreão1,2, Barbara M. Ianni1, Charles Mady1, Evandro Naia1, Carlos H. Rassi1, Cesar Nomura1,
José R. Parga1, Luis F. Avila1, José A. F. Ramires1, Roberto Kalil-Filho1 and Carlos E. Rochitte1*
Abstract
Background: Chagas’ heart disease is an important public health problem in South America. Several aspects of the
pathogenesis are not fully understood, especially in its subclinical phases. On pathology Chagas’ heart disease is
characterized by chronic myocardial inflammation and extensive myocardial fibrosis. The latter has also been
demonstrated by late gadolinium enhancement (LGE) by cardiovascular magnetic resonance (CMR). In three clinical
phases of this disease, we sought to investigate the presence of LGE, myocardial increase in signal intensity in T2-
weighted images (T2W) and in T1-weighted myocardial early gadolinium enhancement (MEGE), previously
described CMR surrogates for myocardial fibrosis, myocardial edema and hyperemia, respectively.
Methods: Fifty-four patients were analyzed. Sixteen patients with the indeterminate phase (IND), seventeen patients
with the cardiac phase with no left ventricular systolic dysfunction (CPND), and twenty-one patients with the
cardiac phase with left ventricular systolic dysfunction (CPD). All patients underwent 1.5 T CMR scan including LGE,
T2W and MEGE image sequences to evaluate myocardial abnormalities.
Results: Late gadolinium enhancement was present in 72.2 % of all patients, in 12.5 % of IND, 94.1 % of the CPND
and 100 % of the CPD patients (p < 0.0001). Myocardial increase in signal intensity in T2-weighted images (T2W)
was present in 77.8 % of all patients, in 31.3 % of the IND, 94.1 % of the CPND and 100 % of the CPD patients
(p < 0.0001). T1-weighted myocardial early gadolinium enhancement (MEGE) was present in 73.8 % of all patients, in
25.0 % of the IND, 92.3 % of the CPND and 94.1 % of the CPD (p < 0.0001). A good correlation between LGE and
T2W was observed (r = 0.72, and p < 0.001).
Conclusions: Increase in T2-weighted (T2W) myocardial signal intensity and T1-weighted myocardial early
gadolinium enhancement (MEGE) can be detected by CMR in patients throughout all phases of Chagas’ heart
disease, including its subclinical presentation (IND). Moreover, those findings were parallel to myocardial fibrosis
(LGE) in extent and location and also correlated with the degree of Chagas’ heart disease clinical severity. These
findings contribute to further the knowledge on pathophysiology of Chagas’ heart disease, and might have
therapeutic and prognostic usefulness in the future.
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Background
Trypanosoma cruzi infection is responsible for the Cha-
gas’ disease (CD) [1] and it is still a public health prob-
lem in South America with an estimated of 13 % of
Latin American population at risk of contracting this
disease. With an annual incidence of 29,925 cases in 21
Latin American countries, this disease still affects ap-
proximately 5.7 million people [2], with an average of
12,500 deaths per year [3]. Chagas’ disease has a disease
burden, measured by disability-adjusted life years that is
7.5 times higher than malaria, which makes it the para-
sitic disease with the highest disease burden in the
Western Hemisphere [4, 5]. Chagas’ heart disease is the
most serious complication of CD, striking approximately
one-third of seropositive individuals and the leading
cause of death from heart failure in Latin America. The
asymptomatic phase can last for decades, corresponding
to the clinical indeterminate phase (IND), until un-
known triggers initiate the progression to arrhythmias
and heart failure in a subset, which represents approxi-
mately one third of the patients.
Myocardial fibrosis has been described in some studies
with advanced Chagas’ heart disease subjects, using
histologic confirmation [6, 7]. T. cruzi DNA can be de-
tected by polymerase chain reaction during the chronic
phases of Chagas’ heart disease in association with in-
flammatory infiltrate [8–10]. The presence of T. cruzi in
combination with moderate to severe inflammation was
demonstrated with the technique of immunohistochem-
istry [11]. Myocardial fibrosis and inflammation (using
the Dallas criteria) were also demonstrated in patients
with Chagas’ disease by histology and correlated to post-
contrast increasing in myocardial signal intensity by ru-
dimentary MR imaging [12].
Myocardial fibrosis in Chagas’ heart disease has also
been demonstrated by cardiovascular magnetic reson-
ance (CMR) using late gadolinium enhancement (LGE)
technique, by few studies [13–15]. Additionally, CMR
has demonstrated to detect myocardial inflammatory ac-
tivity by probing myocardial edema and myocardial
hyperemia in acute viral myocarditis, using T2-weighted
and T1- weighted myocardial early gadolinium enhance-
ment image sequences [16–20], with histological con-
firmation. However, the use of these techniques was
not yet reported in patients with Chagas’ heart disease.
This study aims to investigate the presence of late
gadolinium enhancement, myocardial hyper intensity of
signal in T2-weighted sequence (T2W) and in T1-
weighted myocardial early gadolinium enhancement se-
quence (MEGE). in patients with Chagas’ heart disease
in three distinct and progressive stages of the disease’s
natural history. Assuming that those findings corres-
pond to myocardial fibrosis, edema and hyperemia,
respectively.
Methods
In this cross-sectional study, we enrolled 54 patients
with Chagas’ heart disease to undergo CMR. Patients
with serologic confirmed Chagas’ disease diagnosis were
referred to the study from our cardiomyopathy out-
patient clinic. Exclusion criteria were history of myocar-
dial infarction or coronary artery disease, more than two
risk factors for CAD or diabetes mellitus (for those
patients without anatomical confirmation of coronary ar-
teries free of significant stenosis, by invasive coronary
angiography or by coronary computed tomography angi-
ography), valvular heart disease, previous viral myocardi-
tis, other phases of cardiomyopathy, creatinine clearance
below 30 ml/min/1.72 m2 and a contraindication to per-
form CMR. All patients underwent a brief interview
prior to the MRI exam, which included information on
height, weight, medical history and previous exams. We
enrolled three subgroups at different stages of disease
progression based on a classification of Chagas’ disease
and grouped by the outpatient clinic: 1) a group of 16
patients without evidence of cardiac involvement by
ECG, chest radiography and echocardiography called in-
determinate phase of Chagas’ disease (IND), 2) a group
of 17 patients who had cardiac phase without left ven-
tricular systolic dysfunction (CPND), determined by
ejection fraction equal or superior to 55 % by a routine
clinical echocardiography analysis and electrocardio-
graphic abnormalities (right bundle branch block with
left anterior hemiblock) or 3) a group of 21 patients with
the cardiac phase with left ventricular systolic dysfunc-
tion determined by ejection fraction inferior to 55 % by
echocardiography analysis (CPD). The use of echocardi-
ography for the definition of the left ventricular dysfunc-
tion and for the classification of chagasic cardiopathy
phase followed the recommendation of the current
guidelines for Chagas heart disease [21]. All CMR scans
and image acquisitions were uneventful. All patients
signed written informed consent approved by our local
ethic committee (Comissão de Ética para Análise de Pro-
jetos de Pesquisa (CAPPesq) do Hospital das Clínicas da
Faculdade de Medicina da Universidade de São Paulo)
under number 0054/11.
CMR methods
CMR was performed in all patients with a Philips 1.5 T
scanner (Achieva, Philips, Best, The Netherlands). Im-
ages were acquired and coupled to the ECG during
breath-hold, at left ventricle long and short axis, in the
exact same location in the different image sequences.
This allowed a precise comparison between cardiac
function and regional myocardial structure. Cine images
were acquired using SSFP sequence with TR 3.5 ms, TE
1.5 ms, flip angle 60 °, receiver bandwidth ± 125 kHz,
field of view (FOV) of 35 × 35 cm, 256 × 148 matrix,
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temporal resolution 35 ms, 8.0 mm slice thickness, with
2 mm gap between the slices.
The detection of T2W was performed with a triple
inversion-recovery pulse fast spin-echo (FSE) and long
TE (always TE > 70 ms), with breath-hold, in short axis
view of the left ventricle, which was carefully prescribed
in order to guarantee the presence of an adequate skel-
etal muscle area for reference. In this sequence, we used
the volumetric body coil acquisition to guarantee vol-
ume homogeneity and avoid signal dropout, as usually
occurs with the surface coils. The parameters were: TR
2RR interval, TE 80-120 ms, Echo train length 24 (ETL),
TI 140 ms, slice thickness 10 mm, with no gap (keeping
the same center slice as for cine and LGE sequences)
field of view 34 × 38 cm, matrix 128 × 128. MEGE ac-
quisitions were performed pre and immediately post-
gadolinium injection, with the same scanner parameters
and calibrations. We applied a spin-echo free breathing
sequence, in axial plane tipped inferiorly towards the left
to align with the inferior wall of the left ventricle, with
no change in acquisition parameters before and immedi-
ately after intravenous injection of 0.1 mmol/kg gadolin-
ium based contrast (gadoteric acid, Gd-DOTA, Guerbet
Aulnay-Sous-Bois - France), at a 2 ml/sec rate, followed
by 10 ml of saline. The sequence began immediately
after injection and lasted 3 to 4 min; the images reflect a
gadolinium enhancement for an average time of 2 min.
The sequence parameters were the following: Field of
view should be adjusted to include the left upper arm,
echo train length 2 to 4, slice thickness of 8 to 10 mm,
128 y-lines, and four signals averages.
Following the acquisition of spin-echo images, an add-
itional dose of gadolinium-based contrast (0.1 mmol/kg)
was injected for LGE acquisitions, using a typical
inversion-recovery prepared gradient-echo acquired 10
to 20 min after the contrast, with the following parame-
ters: TR 7.1 ms, TE 3.1 ms, flip angle 20°, cardiac phases
1, views per segment 16 to 32, matrix 256 X 192, slice
thickness 8 mm, gap between slices 2 mm and field of
view 32 to 38 cm, inversion time 150 to 350 ms, receiver
bandwidth 31.25 kHz, number of excitations 1, acquisi-
tion every other heart beat. Additionally, we performed
another sequence as described above but with an inver-
sion time TI of 600 ms for further characterization of
cardiac thrombus.
Data analysis
The tests were analyzed in workstation with the CMR-42
software version 4.0.3 (Calgary Circle Cardiovascular
Imaging Inc., Canada). The analyses were performed by
an experienced professional blinded to the clinical classifi-
cation and LGE results, randomly assigned using the Lake
Louise criteria for myocarditis by CMR [22]. End-systolic,
end-diastolic LV volumes, and LVEF were measured
applying Simpson’s method. Segmental LGE transmurality
and myocardial function were scored using standard LV
17-segment model. The T2W were assessed qualitatively
by visual analysis and assisted by a 2SD thresholding tech-
nique that could be used by the observer to define the seg-
ments involved by myocardial edema. Additionally, a
quantitative analysis used the average signal intensity ratio
of the heart muscle and skeletal muscle, (pectoral or bi-
ceps). Ratios above 1.9 indicate positivity for the presence
of myocardial edema. Patients were considered positive
for myocardial edema if they had at least one of the
above criteria. The assessment of MEGE was performed
by detecting myocardial signal intensity gain after gado-
linium injection and comparing it to the gain occurred
in skeletal muscle, all in the same images. A signal in-
crease ratio superior to 4 was considered positive for
MEGE. If skeletal muscle had excessive increase in sig-
nal, superior to 20 %, myositis was to be considered
and, to avoid underestimation in the MEGE ratio, an
absolute myocardial signal increase superior to 45 %
was used as a positive criterion [17, 23].
Late gadolinium enhancement patterns were classified
as subendocardial, midwall, subepicardial, or transmural.
The analysis included the number of LV segments in-
volved by late gadolinium enhancement and an assisted
automatic quantitative analysis to estimate LGE mass by
a thresholding technique with pixel signal intensity 3
standard deviation above the mean of normal myocardial
considered as myocardial fibrosis. In Chagas cardiomy-
opathy, heterogeneous and patchy myocardial fibrosis is
the most frequent pattern, which challenges the use of
Full Width at Half Maximum (FWHM) technique,
where it is crucial to define a clear homogenous myocar-
dial fibrosis area as a reference. By our knowledge, no
definition on ideal threshold for detecting myocardial fi-
brosis in LGE images of Chagas cardiomyopathy patients
is available. The authors performed a pilot analysis and
felt that 3 standard deviation (SD) cutoff above normal
myocardial signal intensity had the best agreement with
visual LGE in a range of Chagas cardiomyopathy sever-
ity, which led the authors to choose in this study the
3SD threshold instead of 5SD (used in some studies in-
volving hypertrophic cardiomyopathy). Quantification of
late enhancement in the left ventricular myocardium
used CMR42 software (Circle CVI, Calgary Canada).
Statistical analysis
Comparisons of normally distributed continuous vari-
ables were performed by the Student t test and one-way
analysis of variance with Bonferroni test for multiple
comparisons. The Fisher exact test was used for propor-
tions comparisons. The nonparametric test for discrete
variables and non-normal continuous variables was
Kruskal-Wallis rank test. Normality was determined by
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Shapiro-Francia W’ test. Simple linear regression was
used between the MF mass and LVEF, end-diastolic
volume, and end-systolic volume. Stata 8.0 (Stata Corp.,
College Station, Texas) was used, and p < 0.05 (two-
tailed) considered statistically significant. Given the
exploratory nature of the study, formal calculations of
sample size were not performed. Based on an article
published by our group [13], which investigated myocar-
dial fibrosis in 51 patients with similar characteristics,
and considering the myocardial fibrosis and inflamma-
tion as part of the same pathophysiological process, we
chose to include at least 50 patients.
Results
We have analyzed 54 patients, and 47 (87 %) had coron-
ary angiography indicating absence of obstructive lesions
(invasive coronary catheterization or coronary CT clinic-
ally indicated), The seven remaining patients had no
history for coronary artery disease or presence of more
than one risk factor. The mean age was 55.53 ±
11.11 years. The minimum age was 35 years and max-
imum 84 years. The population had similar age within
the three phases of the disease. Regarding gender distri-
bution, our sample showed no significant difference,
however, there is an unequal distribution in the disease
severity between genders, men are in more advanced
stages of disease than women and with more LGE and
T2W (Tables 1 and 2).
The average LVEF was 50.2 ± 15.8 %, (normal > 55 %).
The CPND showed an average LVEF of 35.8 ± 10.8 %,
CPD and the indeterminate phase had 54.0 ± 12.0 % and
65.0 ± 5.7 %, respectively (<0.001). All with statistical
differences by post HOC analysis (Bonferronni). The
indexed end diastolic volumes of the left ventricle were
progressively increased, along with the severity of the
clinical phase. CPD showed an average of 137.0 ±
44.0 ml/m2 (Table 1).
There was significant association between the amount
of LGE, T2W and MEGE with the severity of the clin-
ical phases (p < 0.001), functional class (p < 0.001),
LVEF (p < 0.001), and left ventricular diastolic volume
(p < 0.001) (Tables 1, 2 and 3).
Late gadolinium enhancement
Present in 72.2 % of all patients. Two patients (12.5 %;
mean MF mass of 0.85 ± 2.4 g) of the indeterminate
phase (Fig. 1), sixteen patients (94.1 %; 13.0 ± 10.8 g) of
the CPND (Fig. 2), and all patients of the CPD (Fig. 3),
21 patients; (25.2 ± 11.9 g; p < 0,0001) (Table 3).
T2 weighted image
Present in 77.8 % of all patients. We have identified 3
(18.8 %) indeterminate phase (Fig. 1) patients (mean ex-
tent of 0.31 ± 0.87 segments). The CPND (Fig. 2) had
TW2 in 94.1 %; with 3.24 ± 2.3 segments. All patients
with CPD (Fig. 3) presented TW2 (3.67 ± 1.82 segments;
p < 0,0001) (Table 3). Two patients had altered myocar-
dial and skeletal muscle ratio (>1.9), although had no
segmental T2w detected by the qualitative analyses and
were considered positive (Patients 1 and 33).
Myocardial early gadolinium enhancement
Forty-two patients underwent specified test. It was posi-
tive in 73.8 % of these patients. Three patients with
Table 1 Demographic characteristics, clinical and functional assessment by CMR
Clinical phases Total p
Indeterminate CPND CPD
(n = 16) (n = 17) (n = 21) (n = 54)
Age 57.8 ± 11.9 54.3 ± 10.3 54.7 ± 11.3 55.5 ± 11.1 0.61
Male 3 (18.7 %) 7 (41.1 %) 16 (76.1 %) 26 (48.1 %) 0.02
FC NYHA = I 16 (100 %) 14 (82.4 %) 1 (4.8 %) 31 (57.4 %) <0.001
FC NYHA > I 0 (0) 3 (17.6 %) 20 (95.2 %) 23 (42.6 %) <0.001
RVEDVi (ml/m2) 67.7 ± 14.9 70.4 ± 12.2 78.0 ± 22.7 72.6 ± 18.0 0.19
RVESVi (ml/m2) 25.9a ± 5.6 32.0 ± 9.1 40.8a ± 21.7 33.6 ± 15.8 0.01
RVEF (%) 60.9a ± 7.1 54.7 ± 7.9 49.2a ± 12.8 54.4 ± 10.9 0.04
LVEDVi (ml/m2) 72.0a ± 15.4 84.6b ± 22.7 137.0a, b ± 44.0 101.4 ± 42.6 <0.001
LVESVi (ml/m2) 24.9a ± 6.3 39.7b ± 19.5 90.4a, b ± 42.3 55.0 ± 40.6 <0.001
LVEF (%) 65.0a ± 5.7 54.0a ± 12.0 35.8a ± 10.8 50.2 ± 15.8 <0.001
Mass index(g/m2) 55.2a ± 10.5 70.9 ± 15.8 82.2a ± 27.6 70.6 ± 22.8 0.01
Data are expressed as mean ± SD for numeric variables or absolute and relative frequencies (%) for categorical variables
CPND cardiac phase without left ventricular systolic dysfunction, CPD cardiac phase with left ventricular systolic dysfunctional. LV left ventricle, EF ejection fraction,
EDV end-diastolic volume, ESV end-systolic volume, RV right ventricle. FC functional class, NYHA New York Heart Association
Difference by post hoc analysis (a, b)
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MEGE (25 %) within the indeterminate phase, twelve
(92.3 %) in CPND patients and sixteen (94.1 %) of the
CPD patient group, p < 0,0001 (Table 3 and Fig. 4). Five
patients had signal intensity increases in skeletal muscle,
after contrast, greater than 20 %, considered suggestive
of myositis (Patients 25, 28, 32, 41 and 48). A myocardial
signal intensity increases after contrast superior to 45 %
were considered positive in four individuals (Patients 25,
28, 32 and 41).
The segmental analysis was performed using the 17
segments AHA model, in 54 patients, totalizing 918 seg-
ments. Two hundred and forty-four segments (26.6 %)
were identified with myocardial fibrosis, of which 204
(83.6 %) had segmental dysfunction. In 138 (15.0 %) seg-
ments T2W was detected, of which 102 (73.9 %) had
segmental dysfunction. The coexistence of fibrosis and
T2W was seen in 99 segments (10.8 % of all segments
and 40.6 % of segments with myocardial fibrosis). Seg-
mental dysfunction was detected in 363 segments. Pres-
ence of T2W did not perform as an independent factor
to predict dysfunction when the segment had myocardial
fibrosis, but it showed a significant chance for predicting
segmental dysfunction within segments without myocar-
dial fibrosis (Figs. 5 and 6). A good correlation between
LGE and T2W was noticed (r = 0.72, and p < 0.001)
(Figs. 7 and 8). All segments were involved in at least
one patient, evidencing the diffuse nature of Chagas’
heart disease, although lateral and apical walls were
more frequently affected.
Discussion
CMR stands out amongst imaging techniques in the
identification and quantification of myocardial fibrosis in
Chagas’ heart disease, as has been described previously
[13, 14]. The confirmation of myocardial fibrosis in pa-
tients in the indeterminate phase of the disease, contra-
dicts the paradigm that this phase of the disease should
not present any myocardial damage and place CMR as
the current most sensitive technique to detect myocar-
dial damage in Chagas’ heart disease. [24, 25]. It seems
that patients within the indeterminate phase may have
myocardial fibrosis and T2W in a such low degree that
does not lead to myocardial dysfunction or remodeling and,
therefore, may not be picked up by morphological and
functional traditional methods, such as echocardiogram.
On the other hand, CMR using tissue characterization
techniques have been able to clearly detect these appar-
ent small myocardial tissue abnormalities. This observa-
tion could also indicate that the concept of indeterminate
phase may be outdated facing the new advances in cardiac
imaging technologies such as CMR, and there may be an
intermediate phases to those classically described.
This is the first study to investigate T2W and MEGE
in vivo with a noninvasive tool, such as CMR, in patients
with Chagas’ heart disease. The techniques applied in
this study were well established in some important stud-
ies of myocarditis [16, 17, 19] and its diagnosis criteria
were proposed in a landmark publication [22].
The natural history of indeterminate phase is to evolve
to the cardiac phase in up to one third of this group or
stay a benign condition without considerable deterior-
ation of the myocardial status. Presence of positive cri-
teria for T2W and MEGE in the indeterminate phase
could have prognostic power to predict the evolution to
the cardiac phase. The CPND is of great interest, consid-
ering that there is already a cardiac involvement, espe-
cially in the electric pathway, without significant systolic
myocardial dysfunction. This phase may have also an
unpredictable evolution and, therefore, it could become
a valid maker for etiologic therapy, which is still contro-
versial and awaiting for results of larger trials. Identify-
ing myocardial abnormalities in phases of the disease
with none or minor cardiac damage seems to be a rea-
sonable alert to physicians of witch groups are at greater
risk to develop systolic dysfunction and clinical heart
failure. It also represents a major advance in understand-
ing this disease, besides having therapeutic and prognos-
tic importance.
The presence of myocardial abnormalities in patients
with Chagas’ heart disease is not surprising and has been
demonstrated on prior histological studies. Evidence
suggests that parasites persist in the myocardium and
the inflammatory and immune reactions are primarily
responsible for the pathology. The presence of T. cruzi
Table 2 LGE and T2W among clinical and functional characteristics
LGE p T2W p Total
No Yes No Yes
(n = 15) (n = 39) (n = 14) (n = 40) (n = 54)
Age 57.6 ± 11.9 54.6 ± 10.7 NS 58.1 ± 12.7 54.6 ± 10.5 NS 55.5 ± 11.1
LVEDVi (ml/m2) 23.9 ± 6.1 68.1 ± 41.9 <0.001 24.1 ± 6.4 65.9 ± 42.0 <0.001 55.0 ± 40.6
LVEF (%) 66.4 ± 5.1 43.3 ± 13.5 <0.001 66.7 ± 4.7 44.4 ± 14.1 <0.001 50.2 ± 15.8
Data are expressed as mean ± SD for numeric variables or absolute and relative frequencies (%) for categorical variables
LVEF left ventricle ejection fraction, LVIEDV Left ventricle indexed end-diastolic volume, FC functional class, NYHA New York Heart Association
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Table 3 Presence of LGE, TW2 and MEGE among clinical classification, FC NYHA, gender, LVFE and LVEDVi categories
LGE TW2 MEGE
IND (n = 16) (n = 16) (n = 12)
2 (12,5 %) 3 (18.8 %) 3 (25 %)
Mass (g): 0,85 ± 2,47a Segments: 0.31 ± 0.87 a, b
CPND (n = 17) (n = 17) (n = 13)
16 (94,1 %) 16 (94,1 %) 12 (92.3 %)
Mass (g): 13.00 ± 10.8 a Segments: 3.24 ± 2.3 a
CPD (n = 21) (n = 21) (n = 17)
21 (100 %) 21 (100 %) 16 (94.1 %)
Mass (g): 25.00 ± 11.9 a Segments: 3.67 ± 1.82 b
p <0.0001 <0.0001 <0.0001
LVEF > 55 % (n = 24) (n = 24) (n = 19)
9 (37.5 %) 10 (41.7 %) 8 (42,1 %)
Mass (g): 2.62 g ± 4.19 a Segments: 0.92 ± 1.3 a, b
LVEF =30-55 % (n = 18) (n = 18) (n = 17)
18 (100 %) 18 (100 %) 16 (94,1 %)
Mass (g): 19.60 g ± 11.6 a Segments: 3.94 ± 2.2a
LVEF < 30 % (n = 12) (n = 12) (n = 6)
12 (100 %) 12 (100 %) 6 (100 %)
Mass (g): 29.00 g ± 10.8 a Segments: 3.67 ± 1.8 b
p <0.0001 <0.0001 <0.0001
LVEDVi < 85 (n = 22) (n = 22) (n = 17)
10 (45.5 %) 12 (54.5 %) 9 (52,9 %)
LVEDVi = 85-135 ml/m2 (n = 20) (n = 20) (n = 19)
17 (85.0 %) 16 (80.0 %) 16 (84,2 %)
LVEDVi > 135 ml/m2 (n = 12) (n = 12) (n = 6)
12 (100 %) 12 (100 %) 6 (100 %)
p <0.0001 <0.0001 <0.0001
NYHA FC = 1 (n = 31) (n = 31) (n = 25)
16 (51,6 %) 17 (54,8 %) 15 (60,0 %)
NYHA FC > 1 (n = 23) (n = 23) (n = 17)
23 (100 %) 23 (100 %) 16 (94,1 %)
p <0.0001 <0.0001 <0.0001
Male (n = 26) (n = 26) (n = 19)
23 (88,4 %) 23 (88,4) 17 (89,4 %)
Female (n = 28) (n = 28) (n = 23)
16 (57.1 %) 17 (60.7 %) 14 (60.8 %)
p <0.0001 <0.0001 <0.0001
Total (N = 54) (N = 54) (N = 42)
39 (72.2 %) 40 (74.0 %) 31 (73,8 %)
Data are expressed in absolute and relative (%) frequency
LGE Late Gadolinium Enhancement image, TW2 T2 weighted image, MEGE Myocardial Early Gadolinium Enhancement image, LVEF left ventricular ejection fraction,
LVEDVi Left ventricle indexed end-diastolic volume, IND Indeterminate, CPND Cardiac phase without left ventricular systolic dysfunction, CPD Cardiac phase with
left ventricular systolic dysfunctional, FC Functional class, NYHA New York Heart Association
Difference by post hoc analysis (a, b)
Torreão et al. Journal of Cardiovascular Magnetic Resonance  (2015) 17:97 Page 6 of 11
could be demonstrated using PCR and immunohisto-
chemistry associated with inflammation [8–11]. Other
studies have demonstrated common antigens between T.
cruzi and human myocardial fibers, and they serve to
sustain the autoimmune theory [26, 27]. This hypothesis
states that chronic inflammation is perpetuated regard-
less of the presence of the parasite, as has been shown in
Fig. 1 Apical (a), mid (b) and basal (c) short-axis images of a Chagas’ heart disease patient in the indeterminate phase (patient 54, IND) with T2w
(left column), cine SSFP for anatomical reference (mid column) and LGE (right column). Red arrows indicate increased myocardial signal intensity
(T2W Ratio: 2.5). On the apical short-axis slice one can see a positive T2w image without correspondent LGE
Fig. 2 Short-axis images of a Chagas’ heart disease patient in the
cardiac phase without LV dysfunction (patient 15, CPND). LGE (right)
and T2 weighted (left) images with increased regional myocardial
signal intensity on both techniques (T2W Ratio: 2.6)
Fig. 3 Mid (a) and basal (b) short-axis images of a Chagas’ heart
disease patient in the cardiac phase with LV dysfunction (patient
24, CPD). LGE (right) and T2 weighted (left) images with increased
regional myocardial signal intensity on both techniques (T2W
Ratio: 2.4)
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Fig. 4 MEGE evaluation. Example of a negative case, pre contrast (a) and post contrast (b). Example of a positive case, pre contrast (c) and post
contrast (d)
Fig. 5 Association of segments with LGE and T2W positive, using the AHA segmentation model. Data are expressed as absolute frequency
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some publications that used necropsy confirmation [28],
and may be explained by the presence of cross-reactivity
between these antigens and the immune system host.
The presence of T2W in chronic phase of disease was
related with severe impairment of myocardial status, and
may represent the first in vivo CMR evidence that the
inflammation of Chagas’ disease is perpetuated for an
extended period after the acute phase.
Gutberlet et al. demonstrated the presence of persist-
ent inflammation, confirmed by biopsy in 59 % of a
group of patients with chronic viral myocarditis. This re-
sult differs of that found in this group of chronic Chagas
myocarditis, where 74 % of the individuals had positive
criteria for inflammation. This difference may be ex-
plained by the greater severity of myocardial damage
found in chagasic myocarditis, where the mean LVEF
was 50.2 % for all patients, 54.0 % for CP patients and
35,8 % for CPND patients, while in a chronic viral
myocarditis group the LVEF was found within normal
limits [19].
Limitations
Our study represented the first to attempt an inflamma-
tory characterization in vivo in patients with Chagas’
Fig. 6 LV segmental dysfunction distribution based on the presence or absence of myocardial abnormalities. The presence of T2W increased the
chance of segmental dysfunction in the absence of myocardial fibrosis
Fig. 7 Correlation between segments with LGE and segments with T2W image
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heart disease. Therefore we have faced some novel tech-
nical and clinical challenges. Our study had no control
group, since we found concerning to enroll health sub-
jects to contrast injection, however we used a very well
established criteria for the detection of LGE, T2W and
MEGE, with published historical controls. The edema
and hyperemia criteria were extensively experimented
on prior studies, compared with normal myocardial [16,
17, 19]. The analysis of T2W had a limitation on identi-
fying segmental alteration in some of the cardiac cases
due to LV wall deformation and thinning, especially in
the more functionally impaired segments. The myocar-
dium and skeletal muscle ratio criterion was of great use
to correct discrepancies in those cases. Even though the
analyses were made blinded to clinical classification and
to LGE results, the readers had visual information on
volumes and wall thickness encountered in the T2W se-
quence, what was considered, by the authors, also a limi-
tation. Another important limitation was the lack of T1
and T2 mapping, once pulse sequences were not
available in our site at the time of the acquisition.
Arrhythmia data would be also useful clinical informa-
tion in this scenario, but unfortunately our study was
not designed to investigate VT presence or Rassi’s
scores, which would require a Holter monitoring close
to the CMR acquisition.
Conclusions
CMR enables identification, location and quantification
of myocardial fibrosis, T2W and MEGE on Chagas’ heart
disease, adding potential information on disease severity.
T2W and MEGE can be detected in vivo by CMR in pa-
tients within all clinical phases of Chagas’ heart disease,
not only in the advanced phases but also in the early
indeterminate phase. Moreover, those findings demon-
strated a good biological correlation with the severity of
Chagas’ heart disease, NYHA functional class, left
ventricular ejection fraction, and with the presence of
myocardial fibrosis.
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